Lynparza (olaparib)

pCPA File Number: 22575

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic castration-resistant prostate cancer (mCRPC) in adult patients (in combination with abiraterone and prednisone or prednisolone)

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0319-000

pCPA Engagement Letter Issued:

2024-03-12

Negotiation Process Concluded:

2024-05-08